Retas Skyclavs was one of the biggest in 2023 for $7.3bn US by Biogen rare disease drug estimate 5,000 patients in US and $1.5bn sales 2030….. premium was only 60% on their share price at the time.
2591 ‘s potential patients with only current x 4 indications is x 10 (as per presentations) that of Skyclavs with scope for many more potentially…..
Retas deal x 10 is $10-15bn in sales 2030-2033 US only for the potential future of 2591 as a starting point. Likely $30 bn globally…
Fairly attractive asset.
- Forums
- ASX - By Stock
- NEU
- The NDD box seat
The NDD box seat, page-14
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$20.27 |
Change
-1.370(6.33%) |
Mkt cap ! $2.588B |
Open | High | Low | Value | Volume |
$21.62 | $21.63 | $20.24 | $11.01M | 531.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 1111 | $20.26 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$20.28 | 338 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 1111 | 20.260 |
6 | 6904 | 20.250 |
1 | 852 | 20.230 |
1 | 200 | 20.210 |
6 | 9081 | 20.200 |
Price($) | Vol. | No. |
---|---|---|
20.400 | 755 | 1 |
20.450 | 1111 | 2 |
20.520 | 1854 | 1 |
20.580 | 1854 | 1 |
20.640 | 1854 | 1 |
Last trade - 16.10pm 03/06/2024 (20 minute delay) ? |
|
|||||
Last
$20.37 |
  |
Change
-1.370 ( 5.24 %) |
|||
Open | High | Low | Volume | ||
$21.61 | $21.62 | $20.25 | 138748 | ||
Last updated 15.59pm 03/06/2024 ? |
Featured News
NEU (ASX) Chart |